Better effect of sorafenib on the rhabdoid component of a clear cell renal cell carcinoma owing to its higher level of vascular endothelial growth factor-A production.
Gursah
G
Kats-Ugurlu
Cathy
C
Maass
Carla
C
van Herpen
Rob
R
de Waal
Egbert
E
Oosterwijk
Peter
P
Mulders
Christina
C
Hulsbergen-van de Kaa
William
W
Leenders
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000150:complications; D001557:Benzenesulfonates / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D002986:Clinical Trials as Topic; D003863:Depression / Q000150:complications; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000379:methods; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000627:therapeutic use*; D000077157:Sorafenib; D042461:Vascular Endothelial Growth Factor A / Q000096:biosynthesis*
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D042461:Vascular Endothelial Growth Factor A; D009536:Niacinamide; D000077157:Sorafenib